As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.
Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
It stressed that while the funding came from the Novo Nordisk Foundation, the project itself would be carried out by ...
Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus. A clinical trial ...
2don MSN
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.
German software company SAP overtook Danish healthcare company Novo Nordisk as Europe's largest company by market ...
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback